Haemonetics Sells Blood Processing Facility for $10 Million to Focus on MedTech Innovation

VCBeat (WeChat Official Account: vcbrat) has learned that blood technology company Haemonetics recently announced the sale of a plant in South Carolina to CSL Plasma for $10 million.

Haemonetics, founded in 1971, is a high-tech specialized company that holds a leading position in the global blood technology sector and was listed on the New York Stock Exchange in 1991. The company specializes in blood processing technologies, providing services such as component collection of blood and plasma, surgical kits, and hospital transfusion solutions. It is reported that the factory being sold primarily produces saline and sodium citrate solutions used for plasma exchange or collection.

CSL Plasma, headquartered in Boca Raton, Florida, is a subsidiary of the global biotechnology company CSL Behring and a member of the CSL Group. Headquartered in Melbourne, Australia, CSL employs more than 22,000 people worldwide and develops and provides critical ingredients for life-saving therapies for patients with rare and serious conditions, such as immune deficiencies and bleeding disorders, in over 60 countries.

Upon completion of the transaction, CSL Plasma will assume ownership of the facility’s assets and operational control, and approximately 200 plant employees will have the opportunity to join the company. In addition, the two companies have entered into a transition services agreement, under which Haemonetics will continue to supply products to customers pending regulatory approval of the acquisition.

It is reported that after announcing the transaction, Haemonetics lowered its growth forecast for fiscal year 2020 from the previous 5% to a range of 3% to 5%, while maintaining its adjusted earnings per share (EPS) guidance at $2.80 to $3.00.

Chris Simon, President and Chief Executive Officer of Haemonetics, stated, “The sale of this facility marks a significant step in our asset optimization strategy. We will continue to reallocate resources, focusing investment on areas with the greatest growth potential and intensifying the development of medical technology products, thereby enhancing the effectiveness and efficiency of patient care.”

The Senior Vice President and General Manager of CSL Plasma added, “This transaction is a significant step in our vertical integration of the supply chain. More importantly, it enables CSL Plasma to continue fulfilling its commitment to saving patients’ lives.”

(Compiled by Li Chengping)